Literature DB >> 26341523

The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia.

Steven Knapper1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26341523      PMCID： PMC4800705          DOI： 10.3324/haematol.2015.134023

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  21 in total

1.  Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; B Douglas Smith; Mark J Levis; Steven D Gore; Jacqueline Greer; Catherine Hattenburg; Janet Briel; Richard J Jones; John J Wright; A Dimitri Colevas
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.

Authors:  W G Woods; N Kobrinsky; J D Buckley; J W Lee; J Sanders; S Neudorf; S Gold; D R Barnard; J DeSwarte; K Dusenbery; D Kalousek; D C Arthur; B J Lange
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

3.  Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.

Authors:  Judith E Karp; Antonino Passaniti; Ivana Gojo; Scott Kaufmann; Keith Bible; Tushar S Garimella; Jacqueline Greer; Janet Briel; B Douglas Smith; Steven D Gore; Michael L Tidwell; Douglas D Ross; John J Wright; A Dimitrios Colevas; Kenneth S Bauer
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

4.  Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.

Authors:  Dwella M Nelson; Biju Joseph; Joelle Hillion; Jodi Segal; Judith E Karp; Linda M S Resar
Journal:  Leuk Lymphoma       Date:  2011-07-05

5.  Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.

Authors:  J F Bishop; R M Lowenthal; D Joshua; J P Matthews; D Todd; R Cobcroft; M G Whiteside; H Kronenberg; D Ma; A Dodds
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

6.  Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

Authors:  Richard M Stone; Emanuele Mazzola; Donna Neuberg; Steven L Allen; Arnaud Pigneux; Robert K Stuart; Meir Wetzler; David Rizzieri; Harry P Erba; Lloyd Damon; Jun-Ho Jang; Martin S Tallman; Krzysztof Warzocha; Tamás Masszi; Mikkael A Sekeres; Miklos Egyed; Heinz-August Horst; Dominik Selleslag; Scott R Solomon; Parameswaran Venugopal; Ante S Lundberg; Bayard Powell
Journal:  J Clin Oncol       Date:  2015-03-02       Impact factor: 44.544

7.  Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.

Authors:  I M Hann; R F Stevens; A H Goldstone; J K Rees; K Wheatley; R G Gray; A K Burnett
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

8.  Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; Amanda Blackford; B Douglas Smith; Katrina Alino; Amy Hatfield Seung; Javier Bolaños-Meade; Jacqueline M Greer; Hetty E Carraway; Steven D Gore; Richard J Jones; Mark J Levis; Michael A McDevitt; L Austin Doyle; John J Wright
Journal:  Leuk Res       Date:  2009-12-04       Impact factor: 3.156

9.  Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.

Authors:  Jan Braess; Karsten Spiekermann; Peter Staib; Andreas Grüneisen; Bernhard Wörmann; Wolf-Dieter Ludwig; Hubert Serve; Albrecht Reichle; Rudolf Peceny; Daniel Oruzio; Christoph Schmid; Xaver Schiel; Marcus Hentrich; Christina Sauerland; Michael Unterhalt; Michael Fiegl; Wolfgang Kern; Christian Buske; Stefan Bohlander; Achim Heinecke; Herrad Baurmann; Dietrich W Beelen; Wolfgang E Berdel; Thomas Büchner; Wolfgang Hiddemann
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

Review 10.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Authors:  Robert K Hills; Sylvie Castaigne; Frederick R Appelbaum; Jacques Delaunay; Stephen Petersdorf; Megan Othus; Elihu H Estey; Hervé Dombret; Sylvie Chevret; Norbert Ifrah; Jean-Yves Cahn; Christian Récher; Lucy Chilton; Anthony V Moorman; Alan K Burnett
Journal:  Lancet Oncol       Date:  2014-07-06       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.